Preserving bradykinin or blocking angiotensin II: The cardiovascular dilemma

Dialogues in Cardiovascular Medicine

Volumn 9, Issue 2, 2004, Pages 71-89

  Ferrari, Roberto ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

ACE inhibitor; Angiotensin II; Angiotensin converting enzyme (ACE); AT1 receptor antagonist; Bradykinin; Renin angiotensin system

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRILAT; INDAPAMIDE; LISINOPRIL; LOSARTAN; METALLOPROTEINASE; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; QUINAPRILAT; RAMIPRILAT; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

AGING; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SPECIFICITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART INFARCTION; HEART INJURY; HEART PROTECTION; HEART VENTRICLE REMODELING; HORMONE INHIBITION; HUMAN; HYPERTENSION; HYPERVOLEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MEDICAL DOCUMENTATION; NATRIURESIS; NEUROENDOCRINE SYSTEM; NONHUMAN; PROTEIN FUNCTION; RECEPTOR BLOCKING; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SODIUM RETENTION; TACHYCARDIA; VASOCONSTRICTION;

EID: 4544322313     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
2. Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochiem Biophys Acta. 1971;20:261-265.
3. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:1913-1920.
4. Ferrari R. Effect of ACE inhibition on myocardial ischaemia. Eur Heart J Suppl. 1998;19(suppl J):430-435.
5. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation. 1995;92:3105-3112.
6. Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation. 1996;94:1513-1518.
7. Heymes C, Swynghedauw B, Chevalier B. Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats. Circulation. 1994;90:I328-I3233.
8. Shai SY, Fishel RS, Martin BM, Berk BC, Bernstein KE. Bovine angiotensin converting enzyme cDNA cloning and regulation. Increased expression during endothelial cell growth arrest. Circ Res. 1992;70:1274-1281.
9. Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998;101:1225-1232.
10. Schunkert H. Polymorphism of the angiotensin converting enzyme gene and cardiovascular disease. J Mol Med. 1997;75:867-875.
11. Camblen F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
12. Lindpaintner K, Lee M, Larson MG, et al. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med. 1996;334:1023-1028.
13. Montgomery HE, Clarkson P, Dollery CM, et al. Association of the angiotensin converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96:741-747.
14. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
15. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439-449.
16. Su JB, Barbe F, Crozatier B, Campbell DJ, Hittinger L. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol. 1999;34:700-710.
17. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
18. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
19. Pfeffer MA, Damanski EM, Rosenberg Y, et al. Prevention of events with angiotensin-converting enzyme inhibition (The PEACE Study design). Am J Cardiol. 1998;82:25-30.
20. Wood D, De Backer G, Faergeman O, et al, for the Second joint Task Force of European and other Societies on Coronary Prevention: European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Network. Prevention of coronary heart disease in clinical practice. Eur Heart J. 1998;19:1434-1503.
21. Fenves A, Ram CV. Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans? Curr Hypertens Rep. 2002;4:286-289.
22. Cohn JN, Julius S, Neutel J, et al. Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. Am J Hypertens. 2004;17:134-138.
23. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
24. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
25. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
26. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002;288:2981-2987.
28. CONSENSUS Trial Study Group. Effects of enalapril on mortality to severe congestive heart failure: results ofthe Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
29. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
30. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
31. Ferrari R, on behalf of the PREAMI investigators. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design. Cardiovasc Drugs Ther. 2000;14:671-679.
32. Packer M, Poole-Wilson PA, Armstrong PW, et al, on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibior, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-2318.
33. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chornic heart failure; a dose comparison. Eur Heart J. 1998;19:481-489.
34. Nicolosi L, for the GISSI-3 Investigators. The GISSI-3 echocardiographic study on the effects of lisinopril, nitrates and their combination on left ventricular remodelling in six-week survivors ofacute myocardial infarction. Eur Heart J. 1994;15:327.
35. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
36. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity inpatients with left ventricular dysfunction afier myocardial infarction. N Engl J Med. 1992;327:669-677.
37. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction inpatients with coronary artery disease: the TREND study. Circulation. 1996;94:258-265.
38. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281-1286.
39. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of ACE-inhibitors in humans. Circulation. 1997;95:1115-1118.
40. 1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002;39:634-638.
41. Candido R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246-253.
42. Matsumoto T, Minai K, Horie H, et al. Angiolensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol. 2003;41:1373-1379.
43. Yasuda G, Hasegawa K, Kuji T, et al. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am J Hypertens. 2004;17:14-20.
44. Bartels GL, van den Heuvel FM, van Veldhuisen DJ, van der Ent F, Remme WJ. Acute anti-ischemic effect of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol. 1999;83:332-336.
45. Monishita T, Tsutsi M, Shimokawa H, et al. Long term treatment with perindopril ameliorated dobutamine-induced myocardial ischaemia in patients with coronary artery disease. Jpn J Pharmacol. 2002;88:100-107.
46. Conlin PR, Spence ID, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13:418-426.
47. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
48. Tarnow L, Rossing P, Sato A, Nielsen FS, Ali S, Parving HH. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care. 1998;22:491-494.
49. Yasuda G, Kuji T, Hasegawa K, et al. Safety and efficacy of a biliary-execreted angiotensin converting enzyme (ACE) inhibitor, temocapril, in combination with amlodipine in advanced diabetic nephropathy. Clin Exp Nephrol. 2002;6:229-236.
50. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
51. Pitt B, Segal R, Martinez FA, Meurers G, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet. 1997;349:747-752.
52. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan heart failare survival study ELITE II. Lancet. 2000;255:1582-1587.
53. Cohn JN, Tognoni G, for the Valsartan Heart Failure Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
54. Pfeffer MA, Swedberg K, Granger CB, et al, for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
55. Pfeffer MA, McMurray JV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction of both. N Engl J Med. 2003;349:1893-1906
56. Dickstein K, Kiekshus Y, and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002:360:752-766.
57. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol. 2002;89:18A-25A.
58. Brenner BM, Cooper ME, de Zeeuw D, et al for the RENAAL Study investigators. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med. 2001;345:861-869.